The Indian pharmaceutical industry, recognized globally for its substantial contributions, has faced numerous challenges including high dependency on imported raw materials and regulatory complexities. To address these issues and bolster domestic manufacturing, the Katoch Committee, led by Dr. V.M. Katoch, was formed. The committee’s recommendations, laid out in 2015, aim to revitalize the sector and reduce dependence on imports, particularly from China.
Main Recommendations of the Katoch Committee
1. Establishment of Mega Pharma Parks: The committee recommended the creation of Large Manufacturing Zones (LMZs) or Mega Parks for APIs with integrated facilities like Effluent Treatment Plants (ETPs) and testing facilities. These parks would be maintained by a Special Purpose Vehicle (SPV) and provided at concessional rates to stimulate domestic production.
2. Single Window Clearance: To reduce bureaucratic red tape and encourage ease of doing business, the committee suggested implementing a single window clearance system for drug licensing in India.
3. Formation of National Bulk Drugs Development Authority: This body would oversee and drive the growth of the bulk drugs market, ensuring that India can meet its requirements internally.
4. Empowered Panel of Secretaries: The committee proposed setting up a panel headed by the Secretary of Pharmaceuticals to streamline decisions involving multiple ministries, ensuring faster and more efficient policy implementation.
5. Fiscal and Financial Incentives: Recommendations include tax benefits, soft loans with interest subvention, and financial support for setting up infrastructure in Mega Pharma Parks. These measures are aimed at making the Indian pharmaceutical sector more self-reliant and globally competitive.
6. Incentives for R&D: The committee highlighted the need for stronger industry-academia interaction and suggested measures like tax rebates for upgrading R&D facilities to foster innovation.
7. Strengthening Regulatory Compliance: There was a strong emphasis on improving the quality control standards and regulatory compliance, to maintain trust in Indian pharmaceutical products globally.
Implementation & Impact
The implementation of these recommendations has been gradual and mixed. Some initiatives like the proposal for mega pharma parks have seen progress, while others like the single window clearance system require more robust efforts to be fully realized. The overarching goal remains to make India a global hub for pharmaceuticals, mirroring its position in the generic drugs market.
The Katoch Committee’s recommendations, if implemented effectively, have the potential to significantly transform India’s pharmaceutical landscape. By reducing import dependency, enhancing product quality, and fostering innovation, India can solidify its standing as a global pharmaceutical powerhouse. This strategic shift is not just about economic gains but also about ensuring national health security in a rapidly changing global health environment.
–NSH Digi Desk
